Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2021

Open Access 01-12-2021 | Parkinson's Disease | Research

Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease

Authors: Shulei He, Lu Huang, Ci Shao, Tiejian Nie, Li Xia, Bozhou Cui, Fangfang Lu, Lin Zhu, Bolin Chen, Qian Yang

Published in: Translational Neurodegeneration | Issue 1/2021

Login to get access

Abstract

Background

Blood-based test for predicting disease progression and early diagnosis of Parkinson’s disease (PD) is an unmet need in the clinic. The profiles of microRNAs (miRNAs) are regarded as potential diagnostic biomarkers for human diseases, whereas miRNAs in the periphery are susceptible to the influence of various components. MiRNAs enriched in serum extracellular vesicles (EVs) have demonstrated disease-specific advantages in diagnosis due to their high abundance, stability and resistance to degradation. This study was aimed to screen differentially expressed EV-derived miRNAs between healthy controls and PD patients to aid in diagnosis of PD.

Methods

A total of 31 healthy controls and 72 patients with a diagnosis of PD at different Hoehn and Yahr stages in Tangdu Hospital were included. In total, 185 differentially expressed miRNAs were obtained through RNA sequencing of serum EVs as well as edgeR and t-test analyses. Subsequently, the weighted gene co-expression network analysis (WGCNA) was utilized to identify the commonly expressed miRNAs in all stages of PD by constructing connections between modules, and specifically expressed miRNAs in each stage of PD by functional enrichment analysis. After aligning these miRNAs with PD-related miRNAs in Human miRNA Disease Database, the screened miRNAs were further validated by receiver operating characteristic (ROC) curves and quantitative real-time polymerase chain reaction (qRT-PCR) using peripheral blood EVs from 40 more participants.

Results

WGCNA showed that 4 miRNAs were commonly associated with all stages of PD and 13 miRNAs were specifically associated with different stages of PD. Of the 17 obtained miRNAs, 7 were validated by ROC curve analysis and 7 were verified in 40 more participants by qRT-PCR. Six miRNAs were verified by both methods, which included 2 miRNAs that were commonly expressed in all stages of PD and 4 miRNAs that were specifically expressed in different stages of PD.

Conclusions

The 6 serum EV-derived miRNAs, hsa-miR-374a-5p, hsa-miR-374b-5p, hsa-miR-199a-3p, hsa-miR-28-5p, hsa-miR-22-5p and hsa-miR-151a-5p, may potentially be used as biomarkers for PD progression and for early diagnosis of PD in populations.
Appendix
Available only for authorised users
Literature
1.
Nussbaum R, Ellis C. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003;348(14):1356–64. 
2.
Adler C, Beach T, Hentz J, Shill H, Caviness J, Driver-Dunckley E, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014;83(5):406–12. 
3.
de la Fuente-Fernández R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012;78(10):696–701.
4.
Vilas D, Shaw L, Taylor P, Berg D, Brockmann K, Aasly J, et al. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. Mov Disord. 2016;31(6):906–14.
5.
Poewe W, Seppi K, Tanner C, Halliday G, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3(1):17013.
6.
Hansson O, Janelidze S, Hall S, Magdalinou N, Lees A, Andreasson U, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930–7.
7.
Ravanidis S, Bougea A, Papagiannakis N, Maniati M, Koros C, Simitsi A, et al. Circulating brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease. Mov Disord. 2020;35(3):457–67.
8.
Bartel D. Metazoan microRNAs. Cell. 2018;173(1):20–51.
9.
Sheinerman K, Toledo J, Tsivinsky V, Irwin D, Grossman M, Weintraub D, et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res Ther. 2017;9(1):89.
10.
Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003–8.
11.
Hornung S, Dutta S, Bitan G. CNS-derived blood exosomes as a promising source of biomarkers: opportunities and challenges. Front Mol Neurosci. 2020;13:38.CrossRef
12.
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255–89.
13.
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee J, Lötvall J. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9.
14.
Cheng L, Sharples R, Scicluna B, Hill A. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles. 2014;3(1).
15.
Chen X, Liang H, Zhang J, Zen K, Zhang C. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012;22(3):125–32.
16.
Wang L, Zhang L. Circulating exosomal miRNA as diagnostic biomarkers of neurodegenerative diseases. Front Mol Neurosci. 2020;13:53.
17.
Kalluri R, LeBleu V. The biology function and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.CrossRef
18.
Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559.
19.
Schapira A, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(8):509.
20.
Ng A, Tan Y, Yong A, Saffari S, Lu Z, Ng E, et al. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease. Mol Neurodegener. 2020;15(1):33.
21.
Singh T, Yadav S. Role of microRNAs in neurodegeneration induced by environmental neurotoxicants and aging. Ageing Res Rev. 2020;60:101068.
22.
Soreq L, Guffanti A, Salomonis N, Simchovitz A, Israel Z, Bergman H, et al. Long non-coding RNA and alternative splicing modulations in Parkinson’s leukocytes identified by RNA sequencing. PLoS Comput Biol. 2014;10(3):e1003517.
23.
Hanan M, Simchovitz A, Yayon N, Vaknine S, Cohen-Fultheim R, Karmon M, et al. A Parkinson’s disease CircRNAs resource reveals a link between circSLC8A1 and oxidative stress. EMBO Mol Med. 2020;12(9):e11942.
24.
Zhang J, Chen R, Shi F, Yang P, Sun K, Yang X, et al. Genome-wide data mining to construct a competing endogenous RNA network and reveal the pivotal therapeutic targets of Parkinson’s disease. J Cell Mol Med. 2020;25(13):5912–23.
25.
Wake C, Labadorf A, Dumitriu A, Hoss A, Bregu J, Albrecht K, et al. Novel microRNA discovery using small RNA sequencing in post-mortem human brain. BMC Genomics. 2016;17(1):776.
26.
Hoss A, Labadorf A, Beach T, Latourelle J, Myers R. microRNA profiles in Parkinson’s disease prefrontal cortex. Front Aging Neurosci. 2016;8:36.CrossRef
27.
Mitchell P, Parkin R, Kroh E, Fritz B, Wyman S, Pogosova-Agadjanyan E, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.
28.
Doxakis E. Cell-free microRNAs in Parkinson's disease: potential biomarkers that provide new insights into disease pathogenesis. Ageing Res Rev. 2020;58:101023.CrossRef
29.
Vella L, Hill A, Cheng L. Focus on extracellular vesicles: exosomes and their role in protein trafficking and biomarker potential in Alzheimer’s and Parkinson’s disease. Int J Mol Sci. 2016;17(2):173.
30.
Shi M, Liu C, Cook T, Bullock K, Zhao Y, Ginghina C, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol. 2014;128(5):639–50.
31.
Zhao Z, Chen Z, Zhou R, Zhang X, Ye Q, Wang Y. Increased DJ-1 and α-synuclein in plasma neural-derived exosomes as potential markers for Parkinson’s disease. Front Aging Neurosci. 2018;10:438.CrossRef
32.
Yao Y, Qu M, Li G, Zhang F, Rui H. Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2018;22(16):5278–83.
33.
Barbagallo C, Mostile G, Baglieri G, Giunta F, Luca A, Raciti L, et al. Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases. Cell Mol Neurobiol. 2020;40(4):531–46.
34.
Yu H, Sun T, An J, Wen L, Liu F, Bu Z, et al. Potential roles of exosomes in Parkinson's disease: from pathogenesis, diagnosis, and treatment to prognosis. Front Cell Dev Biol. 2020;8:86.CrossRef
35.
Cressatti M, Juwara L, Galindez J, Velly A, Nkurunziza E, Marier S, et al. Salivary microR-153 and microR-223 levels as potential diagnostic biomarkers of idiopathic Parkinson’s disease. Mov Disord. 2020;35(3):468–77.
36.
Song W, Kothari V, Velly A, Cressatti M, Liberman A, Gornitsky M, et al. Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson’s disease. Mov Disord. 2018;33(4):583–91.
37.
Leggio L, Vivarelli S, L'Episcopo F, Tirolo C, Caniglia S, Testa N, et al. microRNAs in Parkinson’s disease: from pathogenesis to novel diagnostic and therapeutic approaches. Int J Mol Sci. 2017;18(12):2698.CrossRef
38.
Wang X, Zhou Y, Gao Q, Ping D, Wang Y, Wu W, et al. The role of exosomal microRNAs and oxidative stress in neurodegenerative diseases. Oxidative Med Cell Longev. 2020;2020:3232869.
39.
Raposo G, Nijman H, Stoorvogel W, Liejendekker R, Harding C, Melief C, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183(3):1161–72.
40.
Conde-Vancells J, Rodriguez-Suarez E, Embade N, Gil D, Matthiesen R, Valle M, et al. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res. 2008;7(12):5157–66.
41.
Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83..
42.
Kakati T, Bhattacharyya D, Barah P, Kalita J. Comparison of methods for differential co-expression analysis for disease biomarker prediction. Comput Biol Med. 2019;113:103380.
43.
Lavin K, Sealfon S, McDonald M, Roberts B, Wilk K, Nair V, et al. Skeletal muscle transcriptional networks linked to type I myofiber grouping in Parkinson’s disease. J Appl Physiol. 2020;128(2):229–40.CrossRef
44.
Chuang Y, Lu A, Paul K, Folle A, Bronstein J, Bordelon Y, et al. Longitudinal epigenome-wide methylation study of cognitive decline and motor progression in Parkinson’s disease. J Parkinsons Dis. 2019;9(2):389–400.
Metadata
Title
Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease
Authors
Shulei He
Lu Huang
Ci Shao
Tiejian Nie
Li Xia
Bozhou Cui
Fangfang Lu
Lin Zhu
Bolin Chen
Qian Yang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2021
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-021-00249-y

Other articles of this Issue 1/2021

Translational Neurodegeneration 1/2021 Go to the issue

Research

Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1

Review

Mitochondrial links between brain aging and Alzheimer’s disease

Review

Multi-mechanical waves against Alzheimer’s disease pathology: a systematic review

Review

Language training for oral and written naming impairment in primary progressive aphasia: a review

Research

Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients

Research

Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment